Advanced Intestinal Barrier Assessment
The Advanced Intestinal Barrier Assessment measures plasma zonulin, lipopolysaccharide-binding protein, diamine oxidase, and intestinal fatty acid-binding protein to evaluate tight-junction regulation, bacterial translocation, enterocyte mass, and epithelial injury.
4
Biomarkers
Blood (plasma)
Sample
7–10 business days
Turnaround
Yes (8–12 hours)
Fasting
What is the Intestinal Barrier Panel test?
The Advanced Intestinal Barrier Assessment combines plasma markers of tight-junction regulation, bacterial translocation, enterocyte mass, and epithelial injury to evaluate the functional integrity of the intestinal barrier. It is designed for the investigation of suspected increased intestinal permeability — colloquially 'leaky gut' — in patients with unexplained gastrointestinal symptoms, systemic inflammation, or conditions thought to involve barrier compromise. Intestinal permeability is difficult to measure directly, so this panel uses circulating surrogates: zonulin as a marker of tight-junction modulation, LBP as evidence of bacterial translocation, DAO as a gauge of enterocyte mass and histamine-degrading capacity, and I-FABP as a signal of acute epithelial damage. The profile is interpreted as a whole, with corroborating clinical and dietary history, to inform interventions targeting gut health. Practitioners order it primarily in functional and integrative medicine settings, recognising that some markers and thresholds lie outside mainstream gastroenterology consensus.
What does the Intestinal Barrier Panel test measure?
Zonulin is a protein that modulates intercellular tight junctions in the intestinal epithelium by binding to receptors on the enterocyte surface, triggering disassembly of junction proteins and increasing paracellular permeability. It is synthesised and released in response to certain luminal signals, including gluten and enteric pathogens, and plays a physiological role in antigen sampling. Elevated circulating zonulin has been proposed as a marker of intestinal barrier dysfunction.
Zonulin is used in functional medicine as a non-invasive marker of intestinal permeability, with elevations interpreted as evidence of increased 'leaky gut'. However, assay specificity remains contested, and the relationship between plasma zonulin and actual barrier function is not universally accepted in mainstream gastroenterology. It is best used as one component of a broader barrier assessment rather than a stand-alone diagnostic marker.
LBP is an acute-phase protein synthesised by hepatocytes and enterocytes that binds bacterial lipopolysaccharide (LPS, endotoxin) and transfers it to CD14 and TLR4 receptors, initiating innate immune responses. It is part of the host defence against Gram-negative bacteria, but persistent elevation reflects chronic low-grade endotoxaemia and is associated with metabolic inflammation and barrier compromise.
Elevated LBP is a marker of bacterial translocation and intestinal barrier dysfunction, seen in conditions characterised by dysbiosis, increased permeability, and metabolic endotoxaemia — obesity, type 2 diabetes, non-alcoholic steatohepatitis, and inflammatory bowel disease. It correlates with systemic inflammation and cardiometabolic risk and is used to assess the functional integrity of the gut barrier.
Diamine oxidase is an enzyme produced by enterocytes in the small-intestinal mucosa that degrades histamine and other biogenic amines in the gut lumen and during mucosal absorption. It is released into the circulation in proportion to enterocyte mass and mucosal integrity, making it a functional marker of small-bowel enterocyte health.
Low circulating DAO activity suggests reduced enterocyte mass or function, which can impair histamine degradation and contribute to histamine intolerance — symptoms of flushing, gastrointestinal discomfort, and headache after histamine-rich foods. DAO deficiency is seen with mucosal atrophy, inflammatory enteropathy, and certain medications (NSAIDs, some antibiotics). It is used in the assessment of suspected histamine intolerance and as a marker of small-intestinal mucosal health.
I-FABP is a small cytoplasmic protein highly specific to mature enterocytes of the small intestine, involved in intracellular fatty-acid transport. It is released into the circulation when enterocytes are damaged or undergo necrosis, making it a marker of acute intestinal epithelial injury. Its plasma half-life is short (approximately 11 minutes), so it reflects recent or ongoing injury.
I-FABP is used as a biomarker of acute intestinal ischaemia, necrotising enterocolitis, and enterocyte damage from inflammatory, infectious, or mechanical causes. In the context of barrier assessment it reflects recent epithelial injury, though it is more commonly employed in acute care (trauma, sepsis, mesenteric ischaemia) than in chronic functional testing.
Why is the Intestinal Barrier Panel test ordered?
- Investigation of unexplained chronic gastrointestinal symptoms — bloating, discomfort, irregular bowel habit — where structural pathology has been excluded
- Assessment of suspected histamine intolerance, with symptoms such as flushing, headache, or gastrointestinal upset after histamine-rich foods
- Evaluation of patients with inflammatory bowel disease, coeliac disease, or food sensitivities in whom barrier function is a therapeutic target
- Monitoring of barrier integrity in patients with metabolic syndrome, type 2 diabetes, or non-alcoholic steatohepatitis where endotoxaemia is hypothesised
- Investigation of systemic symptoms — fatigue, joint pain, skin manifestations — attributed to dysbiosis or increased intestinal permeability
- Patients with autoimmune conditions or chronic inflammatory states in whom gut-barrier dysfunction is explored as a contributing mechanism
- Follow-up assessment after dietary, probiotic, or mucosal-repair interventions targeting intestinal permeability
Sample collection and turnaround
Sample type
Blood (plasma)
Fasting required
Yes (8–12 hours)
Collection method
Venipuncture at patient service centre
Turnaround
7–10 business days
Collection notes
Phlebotomy required. Abstain from alcohol and vigorous exercise for 24 hours before the draw. Collect fasting plasma (EDTA or citrate, depending on assay requirements). Separate plasma promptly and freeze if not processed immediately. Note all current medications, particularly NSAIDs, proton-pump inhibitors, and antibiotics, as these can interfere with DAO and other markers.
Specimen requirements
Minimum 2 mL plasma per analyte (confirm exact volume and anticoagulant with the lab). Plasma must be separated within 1 hour and frozen at −20 °C or colder if shipment is delayed. Avoid haemolysis.
What can affect Intestinal Barrier Panel results?
Strenuous endurance exercise transiently increases intestinal permeability and circulating I-FABP due to splanchnic hypoperfusion and heat stress; avoid vigorous activity in the 24 hours before the draw.
NSAIDs can reduce DAO activity and damage the mucosa, lowering DAO; some antibiotics (metronidazole, aminoglycosides) inhibit DAO, complicating interpretation of histamine intolerance.
Active inflammation and infection increase zonulin, LBP, and I-FABP acutely; results reflect current disease activity rather than baseline barrier function.
Chronic low-grade endotoxaemia in obesity raises LBP independently of acute barrier compromise, so elevated LBP in this population may reflect metabolic inflammation as much as permeability.
Alcohol increases intestinal permeability and endotoxin translocation; abstain for at least 24 hours before testing to avoid transient elevations of zonulin and LBP.
Reduced gastric acidity can alter small-intestinal bacterial overgrowth and dysbiosis, potentially affecting zonulin and LBP, though the net effect on these markers is not well quantified.
What do Intestinal Barrier Panel results mean?
Elevated
Zonulin elevation suggests increased tight-junction permeability and is seen with gluten exposure, dysbiosis, and inflammatory enteropathies. Elevated LBP indicates bacterial translocation and endotoxaemia, common in metabolic syndrome, obesity, NASH, and IBD. Low DAO points to reduced enterocyte mass or function, consistent with mucosal atrophy, inflammatory enteropathy, or histamine intolerance. Elevated I-FABP reflects recent enterocyte damage — acute ischaemia, trauma, or severe inflammation — and is less commonly elevated in chronic functional assessments.
Normal
Normal values across all four markers suggest intact barrier function and the absence of significant bacterial translocation, enterocyte injury, or histamine-degrading deficiency at the time of testing. However, intestinal permeability can be dynamic, so a single normal result does not exclude intermittent or diet-triggered barrier compromise.
Reduced
Low zonulin and LBP are not clinically significant. Low DAO is the critical finding, suggesting impaired histamine degradation and enterocyte compromise. Low I-FABP is normal and reassuring, indicating the absence of acute epithelial injury.
Note: Zonulin assay specificity is contested — some platforms detect pre-haptoglobin-2 family members — so interpret in the context of the specific method used. LBP is an acute-phase protein and can rise with systemic infection or inflammation unrelated to the gut. DAO activity is influenced by medications and diet. I-FABP is most useful in acute settings; chronic barrier dysfunction is better reflected by zonulin and LBP. This panel is used primarily in functional medicine; thresholds and clinical utility are not universally accepted in mainstream gastroenterology.
Frequently asked questions
Intestinal permeability refers to the ease with which molecules pass through the gut lining. When tight junctions between enterocytes become dysregulated, larger molecules and bacterial products can cross into the bloodstream, triggering inflammation and immune responses. This panel measures markers of that process.
How to access the Intestinal Barrier Panel test
The Intestinal Barrier Panel reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.
Create Free AccountAbout this page
Published: October 7, 2026
Last reviewed: October 7, 2026
- Fasano A. Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiol Rev. (2011)
- Ohlsson B, et al. Diamine oxidase and intestinal barrier function in health and disease. Scand J Gastroenterol. (2019)
- Stehle JR Jr, et al. Lipopolysaccharide-binding protein, a surrogate marker of microbial translocation, is associated with physical function in healthy older adults. J Gerontol A Biol Sci Med Sci. (2012)
- Pelsers MMAL, et al. Fatty acid-binding proteins as plasma markers of tissue injury. Clin Chim Acta. (2005)
- Vanuytsel T, et al. The role of intestinal permeability in gastrointestinal disorders and current methods of evaluation. Front Nutr. (2021)
This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.